 Dear Pharmaceutical Company, My name is Alisa Manzelli, and I was diagnosed with stage 3C low‑grade serous ovarian cancer (LGSOC) in 2019 at just 29 years old. While I am so incredibly grateful to still be here, I am painfully aware that many women with my disease are not as fortunate. In reality, there are extremely limited treatment options for this already difficult-to-diagnose disease that disproportionately affects younger women. In the six years I have been living with LGSOC, I’ve witnessed far too many friends I’ve met along my ovarian cancer journey lose their lives. These women and their families deserve better. That is why I am urging you to partner with LGSOC researchers to study your therapies and expand research into this disease. New treatment options give patients the gift of hope—for birthdays celebrated, milestones reached, and cherished time with the people we love. Exploring these possibilities could be life-changing. For me and countless others, it could mean more time. The clock is ticking, and we desperately need pharmaceutical companies to fight for us. Thank you for your consideration. Your work has the potential to save the lives of so many young women like me. With hope, Alisa Manzelli  Alisa Manzelli with Lili Stander, who passed away from low-grade serous ovarian cancer in July 2024. How you can raise your voice to help drive LGSOC researchSTAAR and our partners Low-Grade Serous Ovarian Cancer Initiative and the International Consortium for Low-Grade Serous Ovarian Cancer are collecting letters from LGSOC patients, caregivers, and advocates to show pharmaceutical companies the urgency to research drugs to treat this rare and underserved patient population. These letters will be bundled and sent directly to pharmaceutical companies whose drugs may have potential to treat LGSOC. If you'd like your voice to be heard, please send your letter to [email protected] by September 1, 2025. AuthorAlisa Manzelli was diagnosed with stage 3C low‑grade serous ovarian cancer in 2019 at 29 years old.
1 Comment
|
RSS Feed
